#1 Clinical Trials Search in Europe

Study on 68Ga-FAPI-46 PET/CT for Cancer Patients with Unclear Results from 18F-FDG PET/CT

2 1 1

What is this study about?

This clinical trial is focused on patients with cancer who have uncertain or unclear results from a standard imaging test called [18F]F-FDG PET/CT. The study is investigating a new imaging method using a substance called 68Ga-FAPI-46, which is given as a solution for injection. This new method, known as [68Ga]Ga-FAPI PET/CT, aims to provide clearer results for detecting cancer in these patients.

The purpose of the study is to evaluate how well the [68Ga]Ga-FAPI PET/CT can identify the presence of cancer in patients who have already undergone the usual diagnostic procedures but still have uncertain results. The study will compare the accuracy of this new imaging method with the standard [18F]F-FDG PET/CT to see if it can better confirm the presence of cancer.

Participants in the study will receive an injection of 68Ga-FAPI-46 and undergo the [68Ga]Ga-FAPI PET/CT scan. The results will be analyzed to determine if this new method provides more accurate information about the presence of cancer compared to the standard imaging test. The study is expected to continue until June 2025.

1 initial visit

Upon joining the study, the patient will attend an initial visit. During this visit, the patient will receive detailed information about the trial, including its purpose and procedures. The patient will have the opportunity to ask questions and provide informed consent to participate in the study.

2 screening

The patient will undergo a screening process to confirm eligibility for the trial. This may include reviewing medical history and performing necessary tests to ensure the patient meets the study criteria.

3 administration of 68Ga-FAPI-46

The patient will receive an injection of 68Ga-FAPI-46, a solution administered through a vein (intravenous use). This step is crucial for the imaging process that follows.

4 PET/CT scan

After the injection, the patient will undergo a PET/CT scan. This imaging procedure helps in detecting the presence of disease. The scan will be conducted to evaluate the accuracy of the imaging in identifying any oncological conditions.

5 follow-up visit

The patient will attend a follow-up visit to discuss the results of the PET/CT scan. The healthcare team will provide information on the findings and any further steps that may be necessary based on the results.

Who Can Join the Study?

  • Must be at least 18 years old.
  • Open to all genders.
  • Must have a suspected or newly diagnosed cancer, or have been previously treated for cancer.
  • Previous cancer treatments must have been completed at least 3 months ago.
  • Must have had a FDG PET/CT scan (a type of imaging test) with unclear results, such as:
    • Suspected primary or secondary cancer lesions (like in lymph nodes or distant spread) with absent or low FDG uptake (a measure of how much the cancer cells absorb a special sugar used in the scan).

Who Cannot Join the Study?

  • Patients who are not suspected of having an oncological disease or do not have a new diagnosis of a tumor.
  • Patients who have not had a previously treated tumor.
  • Patients whose standard clinical or diagnostic tests do not show unclear or uncertain results.
  • Patients who do not have a doubtful or inconclusive result from a PET/CT scan using 18F-FDG (a type of imaging test used to look for cancer).

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Abtkpdj Ubmjp Sgiexywat Lrmiyt Dg Bssnzjc Bologna Italy

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Italy Italy
Recruiting
03.06.2021

Trial locations

Investigated drugs:

68Ga-FAPI is a special type of imaging agent used in PET/CT scans. It helps doctors see certain types of cancer more clearly. In this study, it is used to find out if it can better detect cancer in patients who have unclear results from a different type of scan. This agent works by attaching to specific parts of cancer cells, making them visible on the scan.

18F-FDG is another imaging agent used in PET/CT scans. It is commonly used to detect cancer because it highlights areas of the body that use a lot of sugar, which can indicate the presence of cancer cells. In this study, it is used as a comparison to see if the new agent, 68Ga-FAPI, provides clearer results in cases where the 18F-FDG scan results are uncertain or inconclusive.

Oncological Disease – Oncological diseases refer to a broad category of conditions characterized by the uncontrolled growth and spread of abnormal cells. These diseases can originate in any part of the body and may form solid tumors or affect the blood and lymphatic systems. The progression of oncological diseases varies widely depending on the type and location of the cancer, as well as individual patient factors. In general, cancer cells can invade nearby tissues and spread to distant parts of the body through the bloodstream or lymphatic system, a process known as metastasis. The growth rate and pattern of spread can differ significantly among different types of cancer. Early stages may be asymptomatic, while advanced stages can lead to significant organ dysfunction and other complications.

Trial ID:
2024-518765-96-00
Protocol code:
FAPI-MN-2020
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Venetoclax plus drug combination versus drug combination alone in children with relapsed acute myeloid leukemia

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +8

  • A study to evaluate the efficacy and safety of depemokimab and salbutamol sulfate in patients with chronic obstructive pulmonary disease and type 2 inflammation.

    Recruiting

    3 1 1
    Investigated drugs:
    Belgium Bulgaria Denmark France Germany Greece +6